CREATIC aims to contribute in the field of pharmacoeconomic evaluation of orphan drugs, in particular to sustainably improve access to therapies that can make a major impact on the lives of patients with these specific diseases.
Pharmacoeconomics in rare diseases is associated with challenges and factors arising from the limited prevalence and very specific characteristics of these diseases.
Pharmacoeconomics in the context of rare diseases addresses many specificities:
- Limited data and studies
- High research and development costs
- Individual approach to patients
- Benefits for patients and society
- Issues related to benefit assessment
Our mission in the field of pharmacoeconomic evaluation of orphan drugs is to find innovative and individualized approaches to assess the cost and effectiveness of therapies.
Given the specificities of rare diseases and the difficulties associated with the application of standard technology assessment (HTA) procedures, we focus on the following key aspects:
- • Development of alternative methodologies
- • Assessment of overall benefit
- • Taking socio-economic aspects into account
- • Dialogue with stakeholders
- • Promoting innovative approaches to funding
Our expertise in pharmacoeconomics includes
- Healt-Technology Assessment
- Comparative Effectiveness Research
- Cost-Effectiveness Analysis
- Real-World Data (RWD) Assessement
